Age-Related Immunity to Meningococcal Serogroup C Vaccination
Author Information
Author(s): Richarda M. de Voer, Fiona R. M. van der Klis, Rutger M. Schepp, Ger T. Rijkers, Elisabeth A. M. Sanders, Guy A. M. Berbers
Primary Institution: National Institute of Public Health and the Environment, Bilthoven, The Netherlands
Hypothesis
Does the immune response to the meningococcal serogroup C vaccine change with age?
Conclusion
The study indicates that older children and adolescents show increased persistence of IgM and IgG2 antibodies after vaccination, but with reduced avidity.
Supporting Evidence
- Children vaccinated at older ages showed higher levels of MenC-specific IgG.
- An increase in IgM levels was observed correlating with the persistence of IgG antibodies.
- The avidity of IgG antibodies decreased with age despite higher antibody levels.
- Immunization at older ages resulted in a mixed T cell dependent and independent response.
Takeaway
When kids get the meningococcal vaccine, older kids keep their antibodies longer, but those antibodies aren't as strong.
Methodology
The study used two cross-sectional population-based serum banks to measure MenC polysaccharide-specific IgM, IgG1, and IgG2 levels and their avidity.
Potential Biases
Potential bias due to the reliance on historical controls for comparison.
Limitations
The study does not account for pre-existing immunity in participants before vaccination.
Participant Demographics
Children and adolescents aged 1 to 19 years in the Netherlands.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website